Notable Analyst Rating Changes 05/10: (TPX) (PRU) (KERX) Upgraded; (VRTX) (HGSI) (ORCL) Downgraded

UPGRADES
Raymond James upgrades Tempur-Pedic (NYSE: TPX) from Market Perform to Strong Buy.

Prudential Financial (NYSE: PRU) boosted by two:

• Evercore Partners from Equalweight to Overweight, price target lowered from $71 to $65; and
  
  
• Morgan Stanley from Equal Weight to Overweight with a price target of $66.

BofA/Merrill Lynch lifts Tesoro Corporation (NYSE: TSO) from Neural to Buy.

Keryx Biopharmaceuticals (Nasdaq: KERX) upgraded at two firms:

• Ladenburg Thalmann from Neutral to Buy, new price target of $3; and
  
  
• Roth Capital from Neutral to Buy, price target raised from $4 to $7.

For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades

DOWNGRADES
RBC Capital moves Vertex (Nasdaq: VRTX) from Top Pick to Outperform, its price target raised from $63 to $69.

Leerink Swann cuts Human Genome Sciences (Nasdaq: HGSI) from Outperform to Market Perform, lowering its price target from $22 to $16.

ThinkEquity chops Oracle (Nasdaq: ORCL) from Buy to Hold.

Macquarie downgrades Aon Corp (NYSE: AON) from Outperform to Neutral.

For daily real-time Downgrades go to http://www.streetinsider.com/downgrades

NEW COVERAGE
Benchmark begins Smith & Wesson Holding (Nasdaq: SWHC) with a Buy and $9 price target. Click Here for more color.

Stifel Nicolaus initiates Cree (Nasdaq: CREE) with a Buy and $38 price target.

Goldman Sachs assumes Phillips 66 (NYSE: PSX) at Neutral and $39 target.

Société Générale begins Sanofi (NYSE: SNY) with a Buy rating.

For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA Securities Starts Mobility Global (MBGL) at Neutral
• Adient amends credit deal, adds $500M in incremental term loans
• Weibo Corp (WB) PT Lowered to $6.50 at BofA Securities